Entity

Time filter

Source Type

San Jose, CA, United States

News Article | April 30, 2015
Site: www.businesswire.com

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gfgvcx/global_urinary) has announced the addition of the "Global Urinary Incontinence Products Market 2015-2019" report to their offering. The Global Urinary Incontinence Products market to grow at a CAGR of 8.12% over the period 2014-2019. This report covers the present scenario and the growth prospects of the Global Urinary Incontinence Products market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of different types of urinary incontinence treatment products. Emerging countries such as China, India, South Korea, and Thailand have a growing elderly population who are mostly price sensitive and have limited awareness about urinary incontinence. Growing awareness programs about the disease and personal hygiene, commercial advertisements, and increased disposable income of middle and upper-class consumers have propelled the growth of the market. According to the report, improved living conditions and quality of healthcare are increasing the demand for devices such as urinary catheters for the treatment of urologic disorders. Further, the report states that the economic burden of UUI, which includes direct, indirect, and intangible costs, inhibits the growth of the market.


ATLANTA--(BUSINESS WIRE)--In support of its mission to educate, support and encourage men to make healthier lifestyle choices to prevent disease, the Men’s Health & Wellness Center is pleased to join ZERO - The Project to End Prostate Cancer to present the Dash4Dad 5k Race / 1 Mile Fun Walk / Kids Superhero Dash For Dad on Saturday, June 20, 2015. The race is part of the Great Prostate Cancer Challenge, America’s Premier Men’s Health Event Series, taking place in 40 cities in 2015. The Dash4Dad event will begin at 8:00 A.M., rain or shine, on Saturday, June 20, 2015 in the Home Depot/Costco Parking Lot located at 6400 Peachtree Dunwoody Road in Sandy Springs, GA. Individual runner/walker pre-registration fee is $25 until May 26th, $30 from May 27th through June 20th and $35 the day of the race. Children under 12 pre-registration fee is $15. Snooze for Dudes is $35. Registration forms may be found online at www.zeroprostatecancerrun.org/atlanta. Cancer survivors please contact Joe Blumberg at the information provided below for FREE registration. Survivors receive special recognition at the event. It is anticipated that more than 1,000 participants will join in this event to defeat prostate cancer and maintain screening and patient support programs here in Georgia. Prizes will be awarded to winners in multiple age brackets. Technical T-shirts and refreshments will also be provided for all registered competitors by Dash4Dad sponsors. The event’s local sponsors include: Presenting sponsor Northside Hospital, Georgia Urology, Dewberry Foundation, American Medical Systems, Dendreon, UPS and Radiotherapy Clinics of Georgia. Media sponsors include WXIA 11 Alive, WSB AM750 and AM680 The Fan. The Men’s Health & Wellness Center, a nonprofit center opened in 2007, provides free prostate cancer screening and support groups in the Atlanta area. We provide education and support for men and their loved ones before, during and after a health crisis. For more information, visit www.4dad.org. About ZERO – The Project to End Prostate Cancer We commit ourselves not only to reduce prostate cancer and alleviate the pain from the disease, but to end it. We see a future where all men who have been diagnosed with prostate cancer will be cured or can manage their illness with high quality of life, with the support they need to minimize physical and emotional suffering, and to cope effectively throughout their cancer journey, visit www.zeroprostatecancer.org.


Rieken M.,University of Basel | Kang H.W.,American Medical Systems Inc. | Koullick E.,American Medical Systems Inc. | Bachmann A.,University of Basel
Lasers in Surgery and Medicine | Year: 2010

Background and objective: Anatomic, tissue ablation and coagulation, and histopathologic outcomes of the 150-W 980-nm diode laser selective light vaporization (SLV™) of the prostate in the first survival study of living canines were analyzed. Study design/materials and methods: Ten dogs underwent anterograde SLV™ with the 150-W 980-nm laser delivered by its side-firing fiber (Fusion™). Postoperatively, two dogs were euthanized at 3hours as planned, six at 2-7 days due to complications, and two, without complications, at 8 weeks as planned. Laser energy and time were recorded. Prostates were sectioned, measured, and histologically analyzed after hematoxylin and eosin (H&E), triphenyltetrazolium chloride (TTC), or Gomori trichrome (GT) staining. Results: SLV™ acutely and hemostatically created a 0.6±0.3cm3 cavity in the 3-hour group accompanied by H&E- and TTC-identified coagulation necrosis of up to 9.5mm (6.1±1.2mm) that led to prostatic slough-induced obstruction and perforation in six of eight (75%) surviving animals, necessitating unplanned euthanasia within 2-7 days. H&E- and GT-stained prostates at 8 weeks postoperatively showed large (9.6±1.4cm3) re-epithelialized prostatic cavities with persistent diffuse interstitial Prostatitis and collagenous fibrosis. Conclusion: SLV™ with the 150-W 980-nm diode laser in living canines produced small cavities acutely, and was accompanied by deeply necrotic prostatic slough-induced obstruction and perforation in a majority of animals. A minority survived SLV and had favorable anatomic outcomes whereas histology revealed persisting inflammation. Further in vivo studies and a cautious clinical approach are recommended to finally evaluate the potential of SLV™ with the 150-W 980-nm diode laser. © 2010 Wiley-Liss, Inc. Source


Carson III C.C.,University of North Carolina at Chapel Hill | Mulcahy J.J.,University of Arizona | Harsch M.R.,American Medical Systems Inc.
Journal of Urology | Year: 2011

Purpose Although some studies suggest that most infections associated with inflatable penile prosthesis implantation develop within year 1 after surgery, device related infections have been reported 5 years after implantation or later and the infection risk with time is not well characterized. We previously reported a statistically significantly lower infection rate for original inflatable penile prostheses impregnated with antibiotic treatment with minocycline and rifampin vs nonimpregnated inflatable penile prostheses at 1-year followup. Long-term data are now available on infection revision after initial implantation of antibiotic impregnated vs nonimpregnated prostheses. Materials and Methods We retrospectively reviewed patient information forms voluntarily filed with the manufacturer after the initial implantation of more than 39,000 inflatable penile prostheses to compare the revision rate due to infection for antibiotic impregnated vs nonimpregnated implants between May 1, 2001 and December 31, 2008. Life table analysis was used to evaluate device survival from revision surgery. Results On life table survival analysis initial revision events due to infection were significantly less common in the impregnated vs the nonimpregnated group (log rank p <0.0001). At up to 7.7 years of followup 1.1% of 35,737 vs 2.5% of 3,268 men with impregnated vs nonimpregnated implants underwent initial revision due to infection. Conclusions To our knowledge this long-term outcome analysis provides the first substantial clinical evidence of a decrease in costly infection related revision using an antibiotic impregnated inflatable penile prosthesis. © 2011 American Urological Association Education and Research, Inc. Source


News Article | August 15, 2013
Site: www.massdevice.com

NxThera said it closed on a Series C round worth $18.2 million and won CE Mark approval for its Rezum treatment for benign prostatic hyperplasia. Maple Grove, Minn.-based NxThera’s device uses steam to reduce the size of the prostate to relieve urinary symptoms from BPH, according to NxThera’s website. NxThera did not name any of the investors in its C round, but Arboretum Ventures, American Medical Systems, Aberdare Ventures and GDN Holdings (the investment firm of former Medtronic vice chairman Dr. Glen Nelson) all participated in a $12.6 million Series B round back in 2011. The company said it plans to use the Series C round to back a clinical trial ahead of a bid for U.S. clearance for the Rezum device, to commercialize the treatment in Europe and to look into using its sterile water vapor technology in treating prostate cancer and kidney cancer. "We sincerely appreciate the continued engagement and support of our investors as we move closer to realizing NxThera’s vision of a fundamentally new treatment approach that will transform the experience of urologists and the millions of men they treat who suffer from prostate conditions," president & CEO Bob Paulson said in prepared remarks. "With this round of financing, we are well-positioned to undertake and complete our U.S. BPH pivotal trial, obtain early commercial BPH experience in Europe, and accelerate our prostate and kidney cancer clinical development programs."

Discover hidden collaborations